Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.
Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.
Amgen (NASDAQ: AMGN) will present crucial data from its oncology portfolio at the AACR Annual Meeting in New Orleans, April 8-13, 2022. A highlight will be the late-breaking oral presentation of long-term outcomes from the CodeBreaK 100 trial for LUMAKRAS® (sotorasib), a KRASG12C inhibitor for non-small cell lung cancer (NSCLC), on April 10. Additional data will cover preclinical results from AMG 794 and TNB-928b. Over 40 countries have approved LUMAKRAS, which has been administered to more than 4,000 patients globally.
Amgen (NASDAQ:AMGN) has commenced construction on a new biomanufacturing facility in Holly Springs, North Carolina, aimed to be operational by 2025. This facility will enhance Amgen's capability to meet the rising demand for its medicines targeting severe health issues like cancer and heart disease, creating over 350 high-quality jobs.
The plant will utilize advanced technologies to maximize production efficiency and adhere to strict environmental standards, supporting Amgen's goal of carbon neutrality by 2027.
Amgen will virtually present at the 42nd Annual Cowen Healthcare Conference on March 8, 2022, at 11:10 a.m. ET. Key executives, Murdo Gordon and Peter H. Griffith, will lead the presentation. Interested parties can access the conference via a live webcast on Amgen's website, which will also archive the event for 90 days. Amgen, a leading biotechnology company, focuses on innovative human therapeutics and has been recognized for its workplace and sustainability efforts.
Amgen's Board of Directors has declared a $1.94 per share dividend for the second quarter of 2022. This dividend will be paid on June 8, 2022, to stockholders of record by the close of business on May 17, 2022. Amgen, a leader in biotechnology since 1980, focuses on innovative therapeutics aimed at serious illnesses. The company is recognized for its commitment to sustainability and workplace excellence, being listed among the 25 World's Best Workplaces™ and 100 most sustainable companies globally.
Amgen (NASDAQ:AMGN) announced positive outcomes from a pooled analysis of NAVIGATOR Phase 3 and PATHWAY Phase 2b trials, showcasing TEZSPIRE™ (tezepelumab-ekko) effectively reduced asthma exacerbation rates across various biomarker subgroups. The analysis revealed reductions of 71% in patients with high eosinophil counts, 48% in those with lower counts, and significant effectiveness across seasons, indicating TEZSPIRE's ability to manage severe asthma irrespective of inflammatory drivers. Approved in the U.S., TEZSPIRE is under review in the EU, Japan, and other markets.
Amgen (NASDAQ: AMGN) announced promising results from the CodeBreaK 100 trial for LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated advanced pancreatic cancer. The trial revealed a 21% objective response rate (ORR) and an 84% disease control rate (DCR) across 38 heavily pre-treated patients. The median progression-free survival was 4 months, and overall survival reached nearly 7 months. No new safety signals emerged, with treatment-related adverse events occurring in 42% of patients. Amgen plans to expand the trial to enroll more patients with various tumor types.
Amgen (NASDAQ:AMGN) outlines its growth strategy through 2030, focusing on expanding its global patient reach with innovative medicines. CEO Robert A. Bradway emphasizes a diverse portfolio in significant therapeutic categories, backed by a robust pipeline and strong balance sheet. CFO Peter Griffith projects mid-single digit revenue CAGR and approximately 50% operating margins. Key growth drivers include the launch of biosimilars and the anticipated success of therapies like Otezla and Repatha. Amgen aims to return an average of 60% of net income to shareholders, alongside significant capital investments.
On February 8, 2022, Amgen (NASDAQ: AMGN) provided long-term financial guidance for 2022-2030 during its virtual business review. The company expects to repurchase between $6 billion and $7 billion in shares, with $6 billion targeted for Q1 2022. GAAP diluted EPS guidance is projected between $13.08 and $14.13, while non-GAAP diluted EPS guidance ranges from $17.00 to $18.00. The business review is accessible via Amgen's investor relations website, with a comprehensive press release to follow, covering strategy and operations.
